Original Article
Real-world efficacy of postoperative radiotherapy with a moderate dose-escalation for phyllodes tumors of the breast
Translational Breast Cancer Research
2023;
4:
19
(31 July 2023)
Original Article
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer: a long-term safety and overall survival update from the randomised, double-blind, placebo-controlled, phase 3 trial
Translational Breast Cancer Research
2023;
4:
18
(31 July 2023)
Editorial Commentary
Updates on the preoperative immunotherapy for triple-negative breast cancer
Translational Breast Cancer Research
2023;
4:
17
(30 April 2023)
Review Article
Narrative review on the role of immunotherapy in early triple negative breast cancer: unveiling opportunities and overcoming challenges
Translational Breast Cancer Research
2023;
4:
16
(30 April 2023)
Review Article
HER2-low breast cancer: insights on pathological testing
Translational Breast Cancer Research
2023;
4:
15
(30 April 2023)
Review Article
Breast biopsy techniques in a global setting—clinical practice review
Translational Breast Cancer Research
2023;
4:
14
(30 April 2023)
Review Article
Key points of anti-tumor treatment in breast cancer patients with SARS-CoV-2 infection
Translational Breast Cancer Research
2023;
4:
13
(30 April 2023)
Review Article
The association between perioperative opioids and breast cancer recurrence: a narrative review of the literature
Translational Breast Cancer Research
2023;
4:
12
(30 April 2023)
Original Article
Antibody-drug conjugate monotherapy refines the oncological efficacy as compared to therapy of physicians’ choices in advanced breast cancers: a systematic review and meta-analysis
Translational Breast Cancer Research
2023;
4:
11
(30 April 2023)
Original Article
Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+HER2− metastatic breast cancer
Translational Breast Cancer Research
2023;
4:
10
(30 April 2023)
Editorial Commentary
Advances of HER2 testing for women with breast cancer
Translational Breast Cancer Research
2023;
4:
9
(31 January 2023)
Letter to the Editor
Clinical considerations for estrogen receptor-negative/progesterone receptor-positive/HER2-negative (ER−PR+HER2−) breast cancer
Translational Breast Cancer Research
2023;
4:
8
(31 January 2023)
Review Article
Breast cancer gene expression signatures: development and clinical significance—a narrative review
Translational Breast Cancer Research
2023;
4:
7
(31 January 2023)
Review Article
Prospect of neoadjuvant/adjuvant immunotherapy in early-stage triple-negative breast cancer
Translational Breast Cancer Research
2023;
4:
6
(31 January 2023)
Original Article
A retrospective cohort study comparing reconstructive techniques and outcomes in post-mastectomy triple negative breast cancer patients
Translational Breast Cancer Research
2023;
4:
5
(31 January 2023)
Original Article
Molecular subtypes predict the prognosis of male breast cancer: a retrospective cohort study
Translational Breast Cancer Research
2023;
4:
4
(31 January 2023)
Original Article
Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy
Translational Breast Cancer Research
2023;
4:
3
(31 January 2023)
Clinical Practice Guideline
Chinese Society of Breast Surgery (CSBrS) Practice Guideline 2022
Translational Breast Cancer Research
2023;
4:
2
(31 January 2023)
Meet the Professor
Zefei Jiang: when ideals illuminate reality, more breast cancer patients will benefit from the inclusion of T-DM1 in China’s national medical insurance catalog
Translational Breast Cancer Research
2023;
4:
1
(31 January 2023)
Case Report
Presentation of metastatic breast cancer as a large bowel obstruction in an elderly female with resultant diverting ileostomy: case report
Translational Breast Cancer Research
2022;
3:
38
(31 October 2022)
Original Article: Case Series
Risk-reducing surgery in PALB2 mutations carriers with breast cancer: a case series and literature review
Translational Breast Cancer Research
2022;
3:
37
(31 October 2022)
Editorial
CSCO breast cancer management guidelines 2022: Australian perspective
Translational Breast Cancer Research
2022;
3:
36
(31 October 2022)
Editorial
An engineering feat of small proportions
Translational Breast Cancer Research
2022;
3:
35
(31 October 2022)
Editorial
Differences between Japan and China in perioperative pharmacotherapy of early-stage breast cancer in breast cancer guidelines (2022 edition)
Translational Breast Cancer Research
2022;
3:
34
(31 October 2022)
Review Article
Strategies for the treatment of HER2+ advanced breast cancer based on clinical practice in Chinese patients: a roundtable discussion
Translational Breast Cancer Research
2022;
3:
33
(31 October 2022)